indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Ophthalmology
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Ophthalmology
facebook x icon x icon linkedin linkedin
strategy

Thermo Fisher Scientific invests Rs 160 Cr to advance innovation in antibody research and manufacturing

IMT News Desk

The expansion focuses on advancing antibody research, design, and manufacturing, creating over 100 new skilled roles

Thermo Fisher Scientific’s expanded Research and Development (R&D) Centre of Excellence was officially inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM). This facility is committed to pioneering advances in antibody design, development, and manufacturing. It represents a significant milestone in the company’s efforts to accelerate innovation and scientific collaboration from India.

Dignitaries present at the inauguration included senior officials from Karnataka Digital Economy Mission, KEONICS, the Karnataka Innovation & Technology Society (KITS).

Also present at the inauguration were Gianluca Pettiti, Executive Vice President and Sector President, Life Sciences, Diagnostics and Applied Sector, Thermo Fisher Scientific, Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific and Manoj Prasad, Vice President, IT & Digital Solutions, APAC & MEA, Thermo Fisher Scientific and other senior leaders from the company.

Thermo Fisher has invested over Rs 160 crores in this expansion, reinforcing its long-term commitment to India’s research ecosystem. The expanded 37,000 sq ft facility incorporates advanced automation and analytical platforms to support immunoassays, protein analysis, and cell-based studies. In the coming years, the expansion will create 100+ jobs, strengthening local talent development and contributing to Karnataka’s thriving life sciences ecosystem.

Priyank Kharge, Minister for Electronics, IT & Bt and Rural Development & Panchayat Raj, Government of Karnataka, said, “Karnataka has long positioned itself as a vibrant hub for biotechnology and life sciences. The expansion of Thermo Fisher’s facility is a testament to the state’s continued emphasis of this objective. Through our Karnataka Biotechnology Mission and aligned state policies, we are enabling innovation, nurturing talent, and facilitating collaboration between government, academia and industry. This facility strengthens the state’s capability to contribute meaningfully to India’s broader biotechnology vision.”

Gianluca Pettiti said, “We’re honored to deepen our partnership with the Government of Karnataka. Bengaluru is a strategic hub for Thermo Fisher, and this expansion reflects our long-term commitment to India’s innovation ecosystem. By investing in talent and capabilities here, we will accelerate scientific progress and better serve customers in India and around the world.”

With this expansion, Thermo Fisher’s Bengaluru Centre of Excellence continues to serve as a cornerstone of its global R&D network. Over the past 18 years, the facility has developed more than 2,000 high-quality recombinant antibodies that have contributed to advancements in infectious diseases, antiviral studies, and cancer biology. Its antibody validation program has tested over 25,000 antibodies, while manufacturing capabilities have produced more than 2,000 primary and secondary antibodies, ensuring quality and reproducibility for researchers worldwide.

Dr Manjula N, commented, “This investment aligns well with the state Government’s vision to harness scientific innovation, enable industry-academia linkages, and develop talent for high-end research. Facilities like these catalyze Karnataka’s emergence as a preferred location for research and advanced manufacturing, and will help drive socio-economic growth in the life sciences domain.”

“This expansion reinforces our faith in India’s potential in becoming a leader for life-sciences innovation. Bengaluru continues to anchor our efforts in research, development and product innovation. With this new infrastructure and potential talent infusion, we can accelerate scientific discovery, strengthen our global network, and better support customers in biotech, diagnostics, academia and beyond,” Manoj Prasad added.

Recommended

Dr Reddy’s Laboratories announces science-based net zero climate targets

Fortis Nagarbhavi unveils next generation Mako Robotic Technology for knee joint replacements

Novo Nordisk launches Ozempic in India

Aster DM Healthcare announces Rs 120 Cr commitment for Oncology Radiation LINAC Centres

Improving breast cancer treatment in India: Early detection, empowering patients and the potential of innovation

‘Reading the mind of cancer’: Indian researchers build AI tool OncoMark to predict tumour behaviour

J&J, Asia Pacific Patient Advocacy Group leaders unite to strengthen shared decision-making in lung cancer care

Bengaluru-based Maarga Mind Care expands to Gurgaon

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions